NOV 0 5 2007 W

Box seq

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date: November 2, 2007

By: Mari Bleizerdam

PATENT.

Attorney Docket No. GC819-2-US/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of) Group Art Unit: To be assigned	
JONES, et al.) Examiner: To be assigned	
Serial No.: 10	0/576,331 _{- 1/2})	
Filed: April 18	3, 2006)	
Encoding Se	e Proteases, Nucleic Acids rine Enzymes and Vectors Is Incorporating Same)))) _)	
RES	PONSE TO THE NOTIFICATION	ON OF DEFECTIVE RESPONSE	
P.O Box 145	er for Patents 0 /A 22313-1450		
Sir:			
In res	ponse to the Notification of De	fective Response, mailed on October 2,	
2007, please	find:		
[]	The Combined Declaration and Power of Attorney signed by the		
	inventor(s) and the surcharge of \$130.00 as set forth in 37 C.F.R. §		
	1.16(e);	·	
[]	Petition for a	_Extension of Time;	
[]	Revocation & New Power of Attorney;		

[]

[X]

Preliminary Amendment;

Statement of Sameness;

US Serial No. 10/576,331 Filed: April 18, 2006

Page 2

[X]	Paper copy of Sequence Lis	ting;	
[X]	Diskette copy of Sequence Listing;		
[]	Request for Use of an Identi	cal Computer Readable Form in Another	
	Application Under 37 CFR §	1.821(e);	
[]	Notice to Comply with Requirements for Patent Applications		
	Containing Nucleotide Sequence and/or Amino Acid Sequence		
	Disclosures (copy of Notice	to be returned with response);	
[]	Form PCT/DO/EO/905 (371 Formalities Notice); and		
[X]	Other: FORM PCT/DO/EO/16 (371 Formalities Notice).		
[]	Charge	_ to Deposit Account No. 07-1048.	

The Director is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC819-2-US/B). A duplicate of this paper is enclosed.

Respectfully submitted,

Dated: November 2, 2007

Reg

Kamrin T. MacKnight Reg. No. 38,230

Danisco US Inc., Genencor Division 925 Page Mill Road Palo Alto, CA 94304-1013

Tel.: 650-846-5838

Fax: 650-845-6504

Date Mailed: 10/02/2007

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 04/18/2006
- Copy of the International Search Report filed on 04/18/2006
- Preliminary Amendments filed on 08/29/2006
- Biochemical Sequence Diskette filed on 07/18/2007
- Oath or Declaration filed on 07/18/2007
- U.S. Basic National Fees filed on 04/18/2006
- Priority Documents filed on 04/18/2006
- Specification filed on 04/18/2006
- Claims filed on 04/18/2006
- Abstracts filed on 04/18/2006
- Drawings filed on 04/18/2006

File: MATTER 11/2/07
Final Date: Type: MP

OC000000026107680

Applicant's response filed 07/18/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 12/27/2006 have not been completed.

• This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821

(e) may-be-submitted_in_lieu_of_a_new_CRE.

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO. /	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/576,331	PCT/US04/39066	GC8192USB

FORM PCT/DO/EO/916 (371 Formalities Notice)